Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02762370 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

A Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target
8
Study locations

NCT02762370 is a Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 33 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02762370, a Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).

Conditions Studied

Type 2 Diabetes Mellitus Osteoarthritis of the Knee

Interventions

  • DRUG FX006 32 mg
  • DRUG TCA IR 40 mg

Study Locations (8)

California

  • - Anaheim
  • - El Cajon
  • - North Hollywood

Texas

  • - Dallas
  • - San Antonio

Pennsylvania

  • - Duncansville

South Carolina

  • - Mt. Pleasant

Tennessee

  • - Knoxville

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2016-04
Est. Completion 2016-11
Phase Phase 2

Sponsor

Pacira Pharmaceuticals

88 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02762370

The ClinicalTrials.gov registry entry for NCT02762370 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which FX006 32 mg is the first listed.

NCT02762370 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02762370 about?

NCT02762370 is a clinical study titled "Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes". The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).

What is the current status of trial NCT02762370?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-04. Estimated completion is 2016-11.

What conditions does trial NCT02762370 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Osteoarthritis of the Knee.

What interventions are being tested in trial NCT02762370?

The interventions under investigation include: FX006 32 mg (DRUG), TCA IR 40 mg (DRUG).

Who is sponsoring clinical trial NCT02762370?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02762370 being conducted?

This trial has 8 study locations across California, Pennsylvania, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

Osteoarthritis of the Knee

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.